Figures & data
Table 1 Treatment attributes and levels of cyclooxygenase-2 inhibitors
Table 2 Respondents’ baseline characteristics
Table 3 Preferences of patient group and physician group as estimated by the regression model
Figure 3 Preference weights for benefit–risk attributes for patient and physician groups.
Abbreviations: CV, cardiovascular; FUN, reduction rate in WOMAC physical function scale from baseline; GI, gastrointestinal; PAI, reduction rate in the WOMAC pain scale from baseline; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
![Figure 3 Preference weights for benefit–risk attributes for patient and physician groups.](/cms/asset/e4985776-71f9-4832-ac72-6a58f8fdf208/dppa_a_98228_f0003_b.jpg)
Figure 4 Relative importance of benefit–risk attributes for patient and physician groups.
![Figure 4 Relative importance of benefit–risk attributes for patient and physician groups.](/cms/asset/f4ceb71f-a411-447e-998a-2710d4d7b1a9/dppa_a_98228_f0004_b.jpg)
Table 4 MAR for patient and physician groups